Tags

Type your tag names separated by a space and hit enter

Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists.
Rev Rhum Engl Ed. 1996 Apr; 63(4):255-61.RR

Abstract

Gout is a common disease. Although effective treatments are available for gout, there is some disagreement as to how they should be used. To study prescription patterns in gout, we conducted a questionnaire survey among 2520 rheumatologists. Seven hundred and fifty completed questionnaires were returned over a two-month period. Among respondents, 35.4% worked in a private office, 21% in a hospital and 43.6% in both. The most widely prescribed treatments in acute gout attack were colchicine alone (63%), colchicine with a nonsteroidal antiinflammatory drug (NSAID) (31.7%) and NSAID alone (5.2%), with significant variations according to the type of practice. Mean duration of treatment in acute gout was 18 +/- 16.8 days (range, 3-180 days). Mean time interval between the attack and initiation of therapy with a xanthine oxidase inhibitor was 21.6 +/- 17.2 days (range 0-180); here also, significant variations were seen according to the type of practice. Concomitant symptomatic therapy was prescribed in 97.3% of cases, for a mean duration of 54 +/- 55.4 days (range 2-365). Thirty per cent of responders never prescribed uricosuric agents. The estimated rate of occurrence of treatment-induced attacks increased with the reported interval between the attack and initiation of urate-lowering therapy. Our data demonstrate that French rheumatologists have widely diverging views on how to treat gout. Whether a waiting period is needed between an acute attack and initiation of urate-lowering therapy, and how long this period should be, are unsettled issues that deserve to be studied.

Authors+Show Affiliations

Rozenberg S
Department of Rheumatology, Pitié Teaching Hospital, Paris.
Lang T
No affiliation info available
Laatar A
No affiliation info available
Koeger AC
No affiliation info available
Orcel P
No affiliation info available
Bourgerois P
No affiliation info available

MeSH

AdultAgedAnti-Inflammatory Agents, Non-SteroidalArthritis, GoutyAttitude of Health PersonnelColchicineDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleFranceGoutGout SuppressantsHumansMaleMiddle AgedSurveys and QuestionnairesTreatment Outcome

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8738444

Citation

Rozenberg, S, et al. "Diversity of Opinions On the Management of Gout in France. a Survey of 750 Rheumatologists." Revue Du Rhumatisme (English Ed.), vol. 63, no. 4, 1996, pp. 255-61.
Rozenberg S, Lang T, Laatar A, et al. Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists. Rev Rhum Engl Ed. 1996;63(4):255-61.
Rozenberg, S., Lang, T., Laatar, A., Koeger, A. C., Orcel, P., & Bourgerois, P. (1996). Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists. Revue Du Rhumatisme (English Ed.), 63(4), 255-61.
Rozenberg S, et al. Diversity of Opinions On the Management of Gout in France. a Survey of 750 Rheumatologists. Rev Rhum Engl Ed. 1996;63(4):255-61. PubMed PMID: 8738444.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists. AU - Rozenberg,S, AU - Lang,T, AU - Laatar,A, AU - Koeger,A C, AU - Orcel,P, AU - Bourgerois,P, PY - 1996/4/1/pubmed PY - 1996/4/1/medline PY - 1996/4/1/entrez SP - 255 EP - 61 JF - Revue du rhumatisme (English ed.) JO - Rev Rhum Engl Ed VL - 63 IS - 4 N2 - Gout is a common disease. Although effective treatments are available for gout, there is some disagreement as to how they should be used. To study prescription patterns in gout, we conducted a questionnaire survey among 2520 rheumatologists. Seven hundred and fifty completed questionnaires were returned over a two-month period. Among respondents, 35.4% worked in a private office, 21% in a hospital and 43.6% in both. The most widely prescribed treatments in acute gout attack were colchicine alone (63%), colchicine with a nonsteroidal antiinflammatory drug (NSAID) (31.7%) and NSAID alone (5.2%), with significant variations according to the type of practice. Mean duration of treatment in acute gout was 18 +/- 16.8 days (range, 3-180 days). Mean time interval between the attack and initiation of therapy with a xanthine oxidase inhibitor was 21.6 +/- 17.2 days (range 0-180); here also, significant variations were seen according to the type of practice. Concomitant symptomatic therapy was prescribed in 97.3% of cases, for a mean duration of 54 +/- 55.4 days (range 2-365). Thirty per cent of responders never prescribed uricosuric agents. The estimated rate of occurrence of treatment-induced attacks increased with the reported interval between the attack and initiation of urate-lowering therapy. Our data demonstrate that French rheumatologists have widely diverging views on how to treat gout. Whether a waiting period is needed between an acute attack and initiation of urate-lowering therapy, and how long this period should be, are unsettled issues that deserve to be studied. SN - 1169-8446 UR - https://www.unboundmedicine.com/medline/citation/8738444/Diversity_of_opinions_on_the_management_of_gout_in_France__A_survey_of_750_rheumatologists_ L2 - https://medlineplus.gov/gout.html DB - PRIME DP - Unbound Medicine ER -